Sonoma Pharma (SNOA) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Public company logo of Sonoma Pharmaceuticals Inc. (SNOA)

This EV/EBITDA valuation chart for Sonoma Pharmaceuticals (SNOA) demonstrates a metric of 0.00. Sonoma Pharmaceuticals develops antibacterial agents for tissue regeneration and the treatment of breakouts, minimizing local risks through expansion into Europe and America. The specifics of dermatology make the business crisis-resistant, as the need for infection treatment persists regardless of the economic climate. Growth scales via FDA certifications and the unique Microcyn system, which ensures loyalty within the professional community.

Sonoma Pharmaceuticals Inc. - SNOA Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/17/2026)

Analytical breakdowns for Sonoma Pharmaceuticals

- market price and analyst price targets:
Initial company analysis:SNOA (Sonoma Pharmaceuticals Inc.)
Original product of Sonoma Pharmaceuticals, Inc.

The implementation of AI-controlled robotic bottling lines requires significant capital expenditures, which directly impacts the debt load of Sonoma Pharmaceuticals (SNOA). The EV/EBITDA metric relates the total enterprise value, including net debt, to operating profit, revealing the real value of assets regardless of tax influence. By analyzing the historical EV/EBITDA trend of Sonoma Pharmaceuticals (SNOA), an investor can determine whether the increase in liabilities is justified by future production efficiency or if the asset faces devaluation.

Competitor analysis for Sonoma Pharmaceuticals

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization krystalbio.com KRYS|Total Company Value to Operating Income Before Depreciation Ratio apogeetherapeutics.com (APGE)|ARQT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VCEL - EV/EBITDA Multiple|ORKA: EV/EBITDA Multiple|SMTI - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization DBV Technologies|Enterprise Value to Operating Income Before Depreciation SLSN (solesence.com)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Journey Medical (DERM)|FBRX: Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Empro Corporation EMPG|Sol-Gel Technologies, Ltd. (SLGL) - Company Value to EBITDA|AXIL Brands Inc - EV/EBITDA Multiple|MDCX (Medicus Pharma Ltd.) - Enterprise Value to Operating Income Before Depreciation|Verrica (VRCA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Hoth Therapeutics, Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization biofrontera-us.com|VYNE: Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio QNRX (Quoin Pharmaceuticals Ltd)|EV/EBITDA Multiple Azitra (AZTR)|EV/EBITDA Multiple DRMA (dermatarx.com)|Business Value to Operating Income Before Depreciation ELAB|RVNC: Enterprise Value to EBITDA Ratio